Poseida Therapeutics, Inc.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company’s pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Poseida’s approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral Super piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients. Learn more at www.poseida.com.

Website	http://poseida.com/
Employees	201-500 employees View all Poseida Therapeutics, Inc. employees
Industry	Biotechnology
Headquarter	9390 Towne Centre Dr, 200, San Diego, California 92121, US
Founded	2014
Keywords	Biotechnology, Gene Therapy, Prostate Cancer, Oncology, Immunotherapy, Cell Therapy, Immunology, Regenerative Medicine, Genome Engineering, Immuno-Oncology, Oncology, Gene Editing, Gene Editing, Multiple Myeloma, Car-T Cells, T-Cells, Genome Engineering, Immunology, Multiple Myeloma, Allogeneic, Allogeneic, Adoptive Cell Therapy, Cas-Clover™, Cytotoxic T Lymphocytes, Non-Viral, Poseida, Transposon, Piggybac®, Piggybac® Dna Modification System, T-Cells, Immuno-Oncology, Regenerative Medicine, Biotechnology, Adoptive Cell Therapy, Immunothera